The HMGA2 Knockout HeLa Polyclonal Cells product provides a heterogeneous CRISPR/Cas9-edited cell population in which the HMGA2 gene has been disrupted, generating a versatile loss-of-function model. This polyclonal knockout pool, derived from the HeLa host cell line, enables functional interrogation of HMGA2 without clonal selection artifacts, maintaining genetic diversity while eliminating target gene expression across the population. Researchers can utilize these cells to dissect HMGA2-dependent transcriptional programs and signaling networks in a widely employed cancer cell background.
The host HeLa cell line is an immortalized epithelial line originating from a human cervical adenocarcinoma, positive for human papillomavirus type 18 (HPV18). Derived from the patient Henrietta Lacks, HeLa cells are a foundational model in cancer research, exhibiting rapid proliferation and the abrogation of p53 and retinoblastoma (Rb) tumor suppressor functions via the HPV E6 and E7 oncoproteins. This genetic context provides a permissive environment for oncogene-driven studies, making it particularly relevant for investigating HMGA2??s role in cell cycle deregulation and epithelial-mesenchymal transition.
HMGA2 functions as a chromatin architectural protein and transcriptional regulator, influencing a broad spectrum of oncogenic processes. Its expression is activated by upstream factors such as STAT3, NF-??B, and c-Myc, and is post-transcriptionally suppressed by the let-7 microRNA family. Transcriptional targets promoted by HMGA2 include cyclins CCNA2 and CCNE1, as well as EMT drivers SNAI1 and VIM, while it represses the cyclin-dependent kinase inhibitor CDKN1A (p21). HMGA2 physically interacts with cofactors like NF-??B, PCAF, and p53, integrating signals from TGF-??, Wnt/??-catenin, and PI3K/AKT/mTOR pathways to coordinate proliferation and mesenchymal phenotypes.
In the HeLa background, disruption of HMGA2 is expected to diminish chromatin remodeling at pro-proliferative and EMT gene loci, leading to reduced expression of cell cycle accelerators and mesenchymal markers. This knockout model attenuates oncogenic signaling through the Ras/MAPK cascade and restores expression of tumor suppressors such as p21, partially counteracting the E6/E7-mediated inactivation of p53 and Rb. Consequently, the cells exhibit impaired migration, invasion, and colony-forming capacity, offering a platform to study tumor-suppressive mechanisms in a transformation-competent context.
This edited cell population is suited for a wide range of applications, including transcriptional regulation studies via RNA-seq and ChIP-qPCR, EMT research using migration/invasion assays and immunofluorescence for VIM and CDH1, and functional genomics with proliferation (MTT) and cell cycle flow cytometry. The model also supports senescence-associated ??-galactosidase assays and soft agar colony formation, making it valuable for drug target validation in cervical cancer and beyond. For more details, please contact Ascent Research.
